Cargando…

Efficacy of Leuprolide Acetate 1-Month Depot for Central Precocious Puberty (CPP): Growth Outcomes During a Prospective, Longitudinal Study

INTRODUCTION: Gonadotropin-releasing hormone analogs (GnRHa) are the treatment of choice for CPP. We investigated growth in GnRHa-naïve subjects, treated with leuprolide acetate 1-month depot for CPP. METHODS: This prospective, open-label study had a long-term, observational, follow-up period. Forty...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Peter A, Neely, E Kirk, Fuqua, John, Yang, Di, Larsen, Lois M, Mattia-Goldberg, Cynthia, Chwalisz, Kristof
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3159140/ https://www.ncbi.nlm.nih.gov/pubmed/21860633 http://dx.doi.org/10.1186/1687-9856-2011-7

Ejemplares similares

Leuprolide Acetate 1-Month Depot for Central Precocious Puberty: Hormonal Suppression and Recovery
por: Neely, E. Kirk, et al.
Publicado: (2010)

Clinical development of the GnRH agonist leuprolide acetate depot
por: Chwalisz, Kristof
Publicado: (2022)

Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer
por: Spitz, A, et al.
Publicado: (2012)

Efficacy and Safety of Leuprolide Acetate 6-Month Depot for the Treatment of Central Precocious Puberty: A Phase 3 Study
por: Klein, Karen O, et al.
Publicado: (2023)

Pseudotumor cerebri in patient on leuprolide acetate for central precocious puberty
por: Omar, Anjumanara Anver, et al.
Publicado: (2020)

Multicenter clinical trial of leuprolide acetate depot (Luphere depot 3.75 mg) for efficacy and safety in girls with central precocious puberty
por: Kim, You Jin, et al.
Publicado: (2013)

Treatment with Depot Leuprolide Acetate in Girls with Idiopathic Precocious Puberty: What Parameter should be Used in Deciding on the Initial Dose?
por: Vurallı, Doğuş, et al.
Publicado: (2020)

6-Month Subcutaneous Leuprolide Acetate Effectively Suppresses Clinical Signs of Puberty in Children With Central Precocious Puberty
por: Eugster, Erica A, et al.
Publicado: (2021)

Outcome of girls with central precocious puberty (CPP)
por: Shah, Ruchi, et al.
Publicado: (2015)

Phase 3 Trial of a Small-volume Subcutaneous 6-Month Duration Leuprolide Acetate Treatment for Central Precocious Puberty
por: Klein, Karen O, et al.
Publicado: (2020)

ODP397 Small-volume, Subcutaneous, 6-month Leuprolide Acetate Effectively Reduces Growth Velocity to Prepubertal Levels in Children with Central Precocious Puberty
por: Klein, Karen O, et al.
Publicado: (2022)

THU195 6-Month Subcutaneous Leuprolide Acetate Achieved And Maintained Hormonal And Clinical Suppression In All Weight Groups Of Children With Central Precocious Puberty
por: Miller, Bradley S, et al.
Publicado: (2023)

Central Precocious Puberty (CPP) in Two Girls With Autism Spectrum Disorder (ASD)
por: Moriuchi, Yuko, et al.
Publicado: (2023)

Leuprolide and triptorelin treatment in children with idiopathic central precocious puberty: an efficacy/tolerability comparison study
por: Valenzise, M., et al.
Publicado: (2023)

Elevated Random Luteinizing Hormone is an Unreliable Indicator for Pubertal Suppression in Girls Treated with Monthly Leuprolide for Idiopathic Central Precocious Puberty
por: Wiromrat, Pattara, et al.
Publicado: (2019)

Efficacy of Triptorelin 3-Month Depot Compared to 1-Month Depot for the Treatment of Korean Girls with Central Precocious Puberty in Single Tertiary Center
por: Chung, Lindsey Yoojin, et al.
Publicado: (2021)

The effect of triptorelin and leuprolide on the level of sex hormones in girls with central precocious puberty and its clinical efficacy analysis
por: Wang, Lan, et al.
Publicado: (2021)

Short-term efficacy of 1-month and 3-month gonadotropin-releasing hormone agonist depots in girls with central precocious puberty
por: Jeon, Min Jin, et al.
Publicado: (2021)

A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients
por: Tunn, Ulf W
Publicado: (2011)

Change in Estradiol Levels among Premenopausal Patients with Breast Cancer Treated Using Leuprolide Acetate 11.25 Milligrams 3-Month Depot and Tamoxifen
por: Lee, Young-jin, et al.
Publicado: (2020)

Efficacy of Leuprorelin 3-Month Depot (11.25 mg) Compared to 1-Month Depot (3.75 mg) for Central Precocious Puberty in Chinese Girls: A Prospective Cohort Study
por: Yang, Jianmei, et al.
Publicado: (2022)

Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluation
por: Wex, Jaro, et al.
Publicado: (2013)

Results of a Second Year of Therapy with the 12-Month Histrelin Implant for the Treatment of Central Precocious Puberty
por: Rahhal, Samar, et al.
Publicado: (2009)

Evaluation of Hypersensitivity Reactions with Leuprolide Acetate and Triptorelin Acetate in Children
por: Metbulut, Azize Pınar, et al.
Publicado: (2021)

Effectiveness of a 6-Month 22.5-mg Leuprolide Acetate Depot Formulation With Tamoxifen for Postoperative Premenopausal Estrogen Suppression in Hormone Receptor-Positive Breast Cancer
por: Wu, Zhen-Yu, et al.
Publicado: (2021)

Central precocious puberty in spina bifida children: Guidelines for the care of people with spina bifida
por: Almutlaq, Nourah, et al.
Publicado: (2020)

Precocious puberty in girls
por: Chittwar, Sachin, et al.
Publicado: (2012)

Precocious puberty in children
por: Atta, Irum, et al.
Publicado: (2013)

Management of precocious puberty
por: Tanaka, Toshiaki
Publicado: (2013)

Hepatoblastoma with Precocious Puberty
por: Yhoshu, Enono, et al.
Publicado: (2019)

Pelvic Ultrasound Parameters of Long-Acting Depot Formulation of Leuprorelin in the Treatment of Idiopathic Central Precocious Puberty in Girls
por: Yang, Kun, et al.
Publicado: (2021)

Transient central precocious puberty: a new entity among the spectrum of precocious puberty?
por: Assirelli, Valentina, et al.
Publicado: (2021)

Contemporary issues in precocious puberty
por: Bajpai, Anurag, et al.
Publicado: (2011)

The characteristics of familial precocious puberty
por: Jeong, Hwal Rim, et al.
Publicado: (2015)

Treatment of Central Precocious Puberty
por: Eugster, Erica A
Publicado: (2019)

Genetic factors in precocious puberty
por: Shim, Young Suk, et al.
Publicado: (2021)

Therapeutic Effects of Leuprorelin (Leuprolide Acetate) in Sexual Offenders with Paraphilia
por: Choi, Jong Hyuk, et al.
Publicado: (2018)

An 11-month-old girl with central precocious puberty caused by hypothalamic hamartoma
por: Yoon, Da Young, et al.
Publicado: (2016)

Implicating factors in the increase in cases of central precocious puberty (CPP) during the COVID-19 pandemic: Experience of a tertiary centre of pediatric endocrinology and review of the literature
por: Barberi, C., et al.
Publicado: (2022)

Precocious puberty: A blessing in disguise!
por: Goswami, Soumik, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_q37pfjn2aohgu4jv6uopbrmus2